• $361.5M
    Market Cap
  • 36.93%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2025
12/31/2024
12/31/2023
12/31/2022
Income Statement
Total Operating Revenue
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cost of Revenue
100,000
-88.89%
900,000
N/A
N/A
N/A
N/A
N/A
Gross Profit
-100,000
-88.89%
-900,000
N/A
0
N/A
0
N/A
Sales and Marketing Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Research and Development Expense
-154.2M
+110.46%
-73.3M
+164.83%
-27.7M
+14.10%
-24.3M
-36.84%
Depreciation and Amortization Expense
350,000
+10.06%
318,000
+2.25%
311,000
-2.20%
318,000
-2.45%
Total Operating Expenses
172.5M
+89.79%
90.9M
+117.66%
41.8M
+14.32%
36.5M
-27.62%
Operating Profit
-172.5M
+89.79%
-90.9M
+117.66%
-41.8M
+14.32%
-36.5M
-27.62%
Interest Income
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Expense
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Interest Income and Expense and Net
0
N/A
0
N/A
0
N/A
0
N/A
Total Nonoperating Income and Expense
6.8M
-33.66%
10.3M
+113.89%
4.8M
+310.67%
1.2M
+784.80%
Income before Taxes
-172.5M
+89.79%
-90.9M
+117.66%
-41.8M
+14.32%
-36.5M
-27.62%
Income Taxes
0
N/A
0
N/A
0
N/A
0
N/A
Extraordinary Items
0
N/A
0
N/A
0
N/A
0
N/A
Net Income
-165.7M
+105.54%
-80.6M
+118.15%
-36.9M
+4.51%
-35.4M
-30.18%
Net Income from Continuing Operations Applicable to Common
-165.7M
+105.54%
-80.6M
+118.15%
-36.9M
+4.51%
-35.4M
-30.18%
Basic EPS and Net Income
-2.27
+71.97%
-1.32
+57.14%
-0.84
-38.69%
-1.37
-53.56%
Diluted EPS and Net Income
-2.27
+71.97%
-1.32
+57.14%
-0.84
-38.69%
-1.37
-53.56%
Basic Weighted Average Shares
72.9M
+19.09%
61.3M
+39.53%
43.9M
+70.41%
25.8M
+50.09%
Diluted Weighted Average Shares
72.9M
+19.09%
61.3M
+39.53%
43.9M
+70.41%
25.8M
+50.09%
Balance Sheet
Cash and Cash Equivalents
85.4M
+157.13%
33.2M
+24.18%
26.7M
-0.28%
26.8M
-61.73%
Short-Term Investments
51.4M
-65.76%
150.2M
+150.22%
60.0M
-34.46%
91.6M
+274.04%
Cash and Cash Equivalents and Short-Term Investments
136.9M
-25.40%
183.5M
+111.38%
86.8M
-26.71%
118.4M
+25.21%
Total Current Assets
142.0M
-27.28%
195.3M
+116.58%
90.2M
-25.31%
120.7M
+67.22%
Accumulated Depreciation
1.9M
+22.68%
1.5M
+25.96%
1.2M
+34.03%
914,000
+53.36%
Property and Plant and Equipment and Net
622,000
-29.40%
881,000
+28.80%
684,000
-17.69%
831,000
-20.78%
Total Long-Term Assets
523,000
-12.25%
596,000
-9.56%
659,000
+3.29%
638,000
-4.63%
Total Assets
145.8M
-27.16%
200.2M
+108.71%
95.9M
-24.11%
126.4M
+60.68%
Income Taxes Payable
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Short-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Current Liabilities
64.8M
+166.03%
24.4M
+156.22%
9.5M
-11.20%
10.7M
+21.02%
Total Long-Term Debt
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Long-Term Liabilities
3.0M
-26.99%
4.1M
-13.85%
4.7M
-1.83%
4.8M
-11.30%
Total Liabilities
67.8M
+138.47%
28.4M
+99.88%
14.2M
-8.30%
15.5M
+8.76%
Retained Earnings
-434.8M
+61.55%
-269.2M
+42.75%
-188.6M
+24.37%
-151.6M
+30.41%
Total Stockholders Equity
78.1M
-54.55%
171.8M
+110.24%
81.7M
-26.31%
110.9M
+72.17%
Total Shares Outstanding
83.1M
+30.20%
63.8M
+45.33%
43.9M
+1.48%
43.3M
+144.31%
Cash Flow
Cash from Operating Activities
-113.2M
+59.98%
-70.8M
+111.48%
-33.5M
+21.36%
-27.6M
-34.52%
Capital Expenditures
91,000
-82.33%
515,000
+214.02%
164,000
+64.00%
100,000
-69.97%
Cash from Investing Activities
100.3M
+217.48%
-85.4M
-356.01%
33.4M
+136.67%
-91.0M
-476.35%
Dividends Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash from Financing Activities
65.1M
-59.79%
161.9M
+539,510.00%
30,000
-99.96%
75.3M
+278.46%
Financials Ratio
Gross Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Operating Margin
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Return on Assets
-95.75%
+75.90%
-54.43%
+63.77%
-33.24%
-3.61%
-34.48%
-37.57%
Return on Equity
-132.59%
+108.53%
-63.58%
+65.74%
-38.36%
-4.88%
-40.33%
-38.63%
Revenue Growth
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Current Ratio
2.19
-72.67%
8.02
-15.47%
9.49
-15.89%
11.28
+38.18%
Cash Ratio
1.32
-3.35%
1.36
-51.53%
2.81
+12.30%
2.51
-68.38%
Debt-to-Equity Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Debt-to-Assets Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow